AREXVY | Home

AREXVY is Canada’s 1st RSV vaccine^1*

AREXVY is a vaccine indicated for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.²

Learn more Learn more

Questions about AREXVY?

Contact customer service:

1-855-5-AREXVY (1-855-527-3989) 8:30 a.m.–4:30 p.m. ET, Monday–Friday.

Please consult the Product Monograph at gsk.ca/AREXVY/PM gsk.ca/AREXVY/PM for important information relating to warnings, precautions, adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling 1-800-387-7374.

* Comparative clinical significance unknown.

References:

Data on file. GSK.
AREXVY Product Monograph, GlaxoSmithKline Inc.

Trademarks are owned by or licensed to the GSK group of companies.

Please note: This site is intended for Canadian healthcare professionals only and is not intended as a means for reporting an adverse event (side effect) or complaint for any GlaxoSmithKline product. To report an adverse event or product complaint, please call 1-800-387-7374.

AREXVY is Canada’s 1st RSV vaccine1*

AREXVY is Canada’s 1st RSV vaccine^1*